Innovent Biologics, Inc. (“Innovent” or “the Company”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic and other major diseases, today announced that clinical data on its ORIENT-2 study of TYVYT® (sintilimab injection), an innovative anti-PD-1 antibody co-developed with Eli Lilly and Company,
May 14, 2020
· 4 min read